Health
MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials – News-Medical.Net
A new study reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against SARS-CoV-2, the agent that is causing the current COVID-19 pandemic….
The modified vaccina virus Ankara (MVA) is an attenuated vaccinia virus that has been used as a vector in the already approved Adenovirus-MVA-based Ebola vaccine. A new preprint appearing on the bioRxiv* server reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that is causing the current coronavirus disease 2019 (COVID-19) pandemic. The MVA provides a vector platform for the rapid production…
-
General24 hours agoCanberra man named as doctor accused of rape after suppression order lifted
-
Noosa News23 hours agoBrisbane vs Collingwood live blog: Richmond selects Noah Balta as unbeaten Lions prepare for Magpies test
-
General22 hours agoNT Coalition candidate Lisa Siebert diverges from Jacinta Nampijinpa Price on royal commission call
-
Noosa News23 hours agoMelbourne Market vendors say new rent offer too expensive as eviction threat looms